How Atlantic Union Bankshares’ (AUB) 8.8 Percent Dividend Hike Will Impact Investors

• On October 30, 2025, Atlantic Union Bankshares Corporation’s Board of Directors declared an 8.8% increase in its quarterly common stock dividend to US$0.37 per share and approved a quarterly dividend of US$171.88 per Series A preferred stock share, payable on December 1, 2025.
• This sizable common dividend hike reflects the Board’s positive outlook on the company’s financial health and long-term earnings potential, potentially signaling growing confidence to shareholders and the market.
• We’ll examine how Atlantic Union Bankshares’ dividend increase strengthens its investment narrative around shareholder returns and ongoing financial momentum.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 37 best rare earth metal stocks of the very few that mine this essential strategic resource.

Atlantic Union Bankshares Investment Narrative Recap

To be a shareholder in Atlantic Union Bankshares, you need to believe in its ability to leverage geographic expansion and scale, especially after recent acquisitions, to drive steady loan and deposit growth while maintaining disciplined risk management. The recent dividend increase signals steady confidence from the Board, but does not materially change the company’s most pressing catalyst, successful integration of recent acquisitions, or its main risk, which is ongoing credit performance amid regional economic headwinds.

Among recent updates, the Q3 2025 earnings release is most relevant for context. Net interest income improved year over year, but the company reported a sharp rise in net charge-offs, highlighting the underlying risk of credit quality even as dividend payouts become more attractive. This announcement sits alongside the dividend hike, illustrating the Board’s apparent commitment to rewarding shareholders despite recent volatility and asset quality pressure.

Yet, it’s important for investors to recognize that while dividends are rising, credit quality risk remains an area you’ll want to fully understand before...

Read the full narrative on Atlantic Union Bankshares (it's free!)

Atlantic Union Bankshares' narrative projects $1.9 billion in revenue and $806.7 million in earnings by 2028. This requires 28.7% yearly revenue growth and a $614.8 million increase in earnings from the current $191.9 million.

Uncover how Atlantic Union Bankshares' forecasts yield a $41.56 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Three Simply Wall St Community members have fair value estimates ranging from US$30.79 to US$45.52 per share, showing a wide spectrum of opinions. Their varied perspectives emphasize how credit quality trends may shape future performance, so exploring multiple viewpoints can be valuable.

Explore 3 other fair value estimates on Atlantic Union Bankshares - why the stock might be worth 6% less than the current price!

Build Your Own Atlantic Union Bankshares Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Atlantic Union Bankshares research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Atlantic Union Bankshares research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Atlantic Union Bankshares' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com